David B. Schwartz is an experienced litigator focused on serving clients on both sides of the “v” in all areas of antitrust enforcement, including government investigations, unfair competition, and other complex civil matters. David specializes in “network” or “platform” antitrust matters, ranging from online retail platforms, sports technologies, or multifaceted healthcare networks. David also has market-leading expertise in the 21^st Century Cures Act’s information blocking ban.

Clients value David’s strategic judgment and unique insight into the complex legal issues they face. As a former Lead Investigative Attorney at the U.S. Federal Trade Commission (FTC), David brings an insider’s perspective to the to the pragmatic, actionable guidance he delivers for clients across a broad array of antitrust matters. Some of the world’s leading companies rely on David’s straightforward advice to help them through their most significant challenges, including forward-thinking and proactive strategies for recovery matters, efficiently resolving government investigations, protecting clients’ confidential information, and minimizing antitrust risk.

Prior to joining the firm, David was the FTC’s most experienced platform antitrust investigator and litigator. He previously led high-profile FTC investigations—most notably in the landmark case FTC et al. v. Amazon.com, where he led the FTC's investigation that resulted in filing the largest antitrust lawsuit in the FTC's history. During this time David worked daily with the FTC's top political and staff leadership, the staff and leadership of dozens of partner states, and staff at the European Commission’s Directorate-General for Competition. David was also an Attorney Advisor for FTC Commissioner Rohit Chopra, where he focused on issues ranging from FTC remedies to private equity consolidation.

David also has significant experience in the healthcare sector, having worked extensively on enforcement issues related to pharmaceutical pricing, private equity provider acquisitions, and Medicare Modernization Act patent settlements. He served in the FTC’s Healthcare Division of the Bureau of Competition from 2015-2022, and again in 2024. During his tenure, David led teams in important FTC wins in the Surescripts exclusionary conduct case, was part of the trial team in the AbbVie sham patent litigation, and was a core member of the Actavis reverse settlement payment litigation.

As part of his deep expertise in healthcare competition matters, David advised both Congress and the U.S. Department of Health and Human Services (HHS) on the issue of health IT information blocking. David was the sole competition lawyer to liaise with HHS in drafting the HHS Information Blocking Exceptions, and thus has a deep understanding of the complex health, privacy, safety, and competition issues that underlie an information blocking claim. Today, David provides concrete, practical advice to top health IT companies on how to comply with and enforce the federal ban on information blocking.

Prior to joining the FTC, David was an associate at Quinn Emanuel. He was also a law clerk to the Honorable Sandra Segal Ikuta of the United States Court of Appeals for the Ninth Circuit.

David is widely recognized in the fields of healthcare, technology, and FTC enforcement. He has published articles in Bloomberg and Law360, has appeared on the ABA Antitrust Section’s 'Our Curious Amalgam' Podcast, and has been quoted in The New York Times, The Wall Street Journal, Reuters, and The Guardian.